Over the past 8 years, MD Anderson has made significant contributions to cancer clinical cooperative group trials, including robust accrual, scientific and administrative leadership, and mentoring young faculty to participate in and lead these important national trials. These attributes will be applied to the emerging National Clinical Trial Network (NCTN) with even greater emphasis through this Network Lead Academic Participant (LAP) grant, with the following overall aims:
Aim 1) To provide robust participation in and accrual to Network group clinical trials targeting a broad range of adult patients with common as well as rare cancers;
Aim 2) To promote best practices in the conduct of NCTN-sponsored clinical research and ensure high quality and timely submission of clinical trial-related data and materials as required by specific protocols;
Aim 3) To provide scientific and administrative leadership within affiliated Network Groups, including protocol development, publication authorship, participation in Network committees / NCI Central IRB (CIRB), and attendance at Network Group meetings;
and Aim 4) To mentor junior faculty, research personnel, and trainees in the leadership, conduct, analysis, and reporting of NCTN and other clinical trials. This LAP utilizes a Multiple Principal Investigator (PI) Plan to apply the demonstrated and complementary cooperative group leadership skills and expertise of 3 investigators: Dr. Cathy Eng, Dr. Kelly Hunt, and Dr. Ritsuko Komaki. In addition, investigators representing the disciplines of pathology, diagnostic imaging, gynecological oncology, surgery, and translational research will play key roles In cooperative group trial conduct and mentorship of young faculty. Oversight of trial accrual and data quality, fund management, centralized communications, and administrative support will be coordinated through the LAP Operations Center under the leadership of an experienced Program Administrator. An Executive Committee will ensure timely inter-Network group communications, effective study prioritizations, review and resolution of any accrual obstacles or data quality issues, and identification of junior facult across the institution as candidates for mentorship and/or leadership roles in Network clinical trials or committees.

Public Health Relevance

The UT MD Anderson Cancer Center Network Lead Academic Participating (LAP) Site grant will provide scientific and administrative leadership to conduct cancer research within the clinical cooperative groups. With enhanced centralized coordination of related activities, this grant will assist with robust accrual across all cooperatie groups and will assist in the development of innovative cancer treatment options, including the conduct of multidisciplinary clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180858-01
Application #
8605951
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-15
Project End
2019-02-28
Budget Start
2014-04-15
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Hospitals
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77030
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Gounder, Mrinal M; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379:2417-2428
Rosenkranz, Kari M; Ballman, Karla; McCall, Linda et al. (2018) The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. Ann Surg Oncol 25:2858-2866
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Li, Daneng; McCall, Linda M; Hahn, Olwen M et al. (2018) Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 171:325-334
Ristau, Benjamin T; Manola, Judi; Haas, Naomi B et al. (2018) Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol 199:53-59
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2018) Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol :JCO2018788620
Wong, Yu-Ning; Manola, Judith; Hudes, Gary R et al. (2018) Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clin Genitourin Cancer 16:e315-e322
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67

Showing the most recent 10 out of 77 publications